HSP90AB1 and night blindness: Unfortunately, a 2018 phase 2 clinical study showed that, despite the efficiency of the dual inhibition of JAK2 and HSP90, the HSP90 inhibitor AUY922 induced severe adverse effects including decreased visual acuity, night blindness and gastrointestinal bleeding [52].